Physician profile
Meredith Barlow
NPI 1962821637
$1,827.27
in general payments reported to CMS, 2019-2025
21 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $82.46 · 2021: $13.67 · 2022: $103 · 2023: $45.89 · 2024: $447 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.63 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $210.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $140.24 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.07 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $138.08 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $132.25 | 2021-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $124.08 | 2019-2024 | |
| Pfizer INC. | $104.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $96.33 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $62.56 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Aimmune Therapeutics, INC. | $52.59 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $49.26 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $49.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $43.80 | 2022 | |
| Coopersurgical, INC. | $22.22 | 2025 | Paragard T 380a |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $22.02 | 2025 | |
| Viatris Specialty LLC | $20.17 | 2025 | Yupelri |
| Lundbeck LLC | $18.98 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.15 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $16.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.